Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Glioblastoma 7Congenital Abnormalities 7Lymphoma, Non-Hodgkin 6Lymphoma, Mantle-Cell 6Gliosarcoma 6Burkitt Lymphoma 6Astrocytoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Myeloproliferative Disorders 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Breast Neoplasms 5Brain Neoplasms 5Oligodendroglioma 4Medulloblastoma 4Lymphoma, Large-Cell, Immunoblastic 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Carcinoma, Renal Cell 4Breast Neoplasms, Male 4Blast Crisis 4Anemia, Refractory, with Excess of Blasts 4Waldenstrom Macroglobulinemia 3Sezary Syndrome 3

Interventions

Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hemangioblastoma × Vorinostat × Clear all
NCT02108002 2018-09-14

Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
7 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡